Midwest healthcare startups raise more than $1 billion in first half of 2016

Midwest healthcare startups are booming so far this year, according to a new report from Cleveland-based BioEnterprise.

In total, Midwest healthcare companies raised more than $1 billion in new equity investments in the first half of 2016, the largest amount raised over a six-month period since BioEnterprise began publishing the report in 2005.

Chicago raised the most money among cities in the Midwest with $260 million, Minneapolis was second at $226 million and St. Louis was third with $143 million. Illinois raised the most money among other Midwestern states in large part to Chicago’s success.

“Not only have we seen a record first-half, but we are also seeing some of the largest individual deals since BioEnterprise started tracking these numbers,” said Aram Nerpouni, president and CEO or BioEnterprise, in a statement.

Chicago-based Accretive Health, which creates revenues cycles solutions for providers, raised $200 million.

When broken into categories, healthcare IT, software and services companies received the most funding with a whopping $538 million, 51 percent of the total funding. Biotech and pharmaceutical companies received $280 million while medical device companies got $226 million.

To read the full report, click here.

 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.